Drugs / Proflavine Hemisulfate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 0 | NCT02790853 Background | May 2016 → May 2026 overdue | lip and oral cavity carcinoma, mouth disorder, preneoplastic lesion | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT01384227 Background | Feb 2009 → Jul 2011 | Barrett esophagus | Anandasabapathy, Sharmila, M.D. | Completed | No outcome recorded |
| Phase 1/2 | NCT04563754 Background | Jul 2019 → Mar 2024 | anal canal carcinoma in situ | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT06435286 Background | Feb 2025 → Mar 2027 expected | squamous cell neoplasm | Baylor College of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Proflavine Hemisulfate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02790853 ↗ |
| Modality | Diagnostic / imaging agent | “a topical contrast agent” PMID 36729506 ↗ Feb 2023 |
| Route | Topical | “Applied on mucosa” NCT02790853 ↗ |